CA3130433C - Chimeric F/G Vaccine Against RSV - Google Patents

Chimeric F/G Vaccine Against RSV

Info

Publication number
CA3130433C
CA3130433C CA3130433A CA3130433A CA3130433C CA 3130433 C CA3130433 C CA 3130433C CA 3130433 A CA3130433 A CA 3130433A CA 3130433 A CA3130433 A CA 3130433A CA 3130433 C CA3130433 C CA 3130433C
Authority
CA
Canada
Prior art keywords
rsv
protein
seq
added
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3130433A
Other languages
English (en)
French (fr)
Other versions
CA3130433A1 (en
Inventor
Ryo YAMAUE
Satoshi KAMAKURA
Mihoko MATSUO
Masaharu Torikai
Hiroaki Mori
Original Assignee
KM Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KM Biologics Co Ltd filed Critical KM Biologics Co Ltd
Publication of CA3130433A1 publication Critical patent/CA3130433A1/en
Application granted granted Critical
Publication of CA3130433C publication Critical patent/CA3130433C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3130433A 2019-02-28 2020-02-27 Chimeric F/G Vaccine Against RSV Active CA3130433C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019036206 2019-02-28
JP2019-036206 2019-02-28
PCT/JP2020/008187 WO2020175660A1 (ja) 2019-02-28 2020-02-27 Ｒｓｖ ｆ／ｇキメラワクチン

Publications (2)

Publication Number Publication Date
CA3130433A1 CA3130433A1 (en) 2020-09-03
CA3130433C true CA3130433C (en) 2025-03-11

Family

ID=72238588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3130433A Active CA3130433C (en) 2019-02-28 2020-02-27 Chimeric F/G Vaccine Against RSV

Country Status (8)

Country Link
US (1) US12121578B2 (https=)
EP (1) EP3932424A4 (https=)
JP (1) JP7253034B2 (https=)
KR (1) KR102679227B1 (https=)
CN (1) CN113543803B (https=)
AU (1) AU2020227545B2 (https=)
CA (1) CA3130433C (https=)
WO (1) WO2020175660A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357643B (zh) * 2023-10-12 2024-06-18 广州佰芮慷生物科技有限公司 一种用于预防呼吸道合胞病毒的疫苗及制备方法
CN117462667B (zh) * 2023-11-10 2025-02-25 上海生物制品研究所有限责任公司 一种复合佐剂及其在疫苗制备中的应用
WO2025149032A1 (en) * 2024-01-11 2025-07-17 Immorna (hangzhou) Biotechnology Co., Ltd. Respiratory syncytial virus vaccine compositions and their use
WO2025263563A1 (ja) * 2024-06-20 2025-12-26 Ｋｍバイオロジクス株式会社 ＲＳＶ ＦＧキメラｍＲＮＡワクチン

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588536B2 (ja) 1977-05-31 1983-02-16 株式会社東芝 マグネトロン
JPS588536U (ja) 1981-07-06 1983-01-20 株式会社ダイフク 組立て作業ラインからの被搬送物搬出装置
JPS6162751U (https=) 1984-09-29 1986-04-28
KR101054735B1 (ko) 2001-07-06 2011-08-05 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 유전자 재조합 에카린 및 그를 제조하는 방법
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2008114149A2 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
WO2009055711A2 (en) 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies
JP5450985B2 (ja) 2008-06-06 2014-03-26 三郎 齋藤 真核細胞において組換えタンパク質を細胞外に放出させるためのポリヌクレオチド
US20110177117A1 (en) 2008-07-18 2011-07-21 Normand Blais Chimeric respiratory syncytial virus polypeptide antigens
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
HUE028085T2 (en) * 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
RU2014117068A (ru) * 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2975052B1 (en) * 2013-03-15 2020-09-23 Xiamen University Epitope of rsv fusion protein and antibody identifying same
US20150166610A1 (en) * 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
CN104293741A (zh) * 2014-10-10 2015-01-21 武汉大学 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
WO2016144675A1 (en) 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法

Also Published As

Publication number Publication date
CA3130433A1 (en) 2020-09-03
JPWO2020175660A1 (https=) 2020-09-03
AU2020227545B2 (en) 2023-10-19
CN113543803B (zh) 2024-10-29
US12121578B2 (en) 2024-10-22
KR102679227B1 (ko) 2024-06-28
US20220111035A1 (en) 2022-04-14
EP3932424A1 (en) 2022-01-05
AU2020227545A1 (en) 2021-10-14
KR20210134670A (ko) 2021-11-10
WO2020175660A1 (ja) 2020-09-03
JP7253034B2 (ja) 2023-04-05
CN113543803A (zh) 2021-10-22
EP3932424A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
US12005115B2 (en) Epstein-barr virus vaccines
CA3130433C (en) Chimeric F/G Vaccine Against RSV
Rigter et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles
US20230321217A1 (en) Compositions comprising complexes displaying antigens and methods of using the compositions
CN116096407A (zh) 重组人偏肺病毒f蛋白及其用途
CN117126291B (zh) 痘病毒重组嵌合抗原、其亚单位疫苗及其应用
US20130315916A1 (en) Respiratory syncytial virus vaccine
KR20250071244A (ko) 융합 전 형태의 호흡기 세포융합 바이러스 재조합 융합 단백질, 이의 제조 방법 및 용도
CN113924113A (zh) 季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用
TW201706290A (zh) 用於增進對抗登革熱病毒之安全性及免疫力的替換抗原決定位疫苗
KR102765237B1 (ko) Rsv의 f 단백질-항체 복합체 및 이를 포함하는 조성물
JP2025533612A (ja) 融合前コンフォメーションを持つ呼吸器合胞体ウイルス組み換え融合タンパク質、その調製方法及び使用
US11905313B2 (en) Recombinant RSV G proteins and their use
HK40061992A (en) Rsv f/g chimeric vaccine
HK40061992B (zh) Rsv f/g嵌合疫苗
EP3202780A1 (en) Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily
AU2021285997A1 (en) Live attenuated respiratory syncytial virus
US20240226276A1 (en) Compositions and methods for mucosal vaccination against sars-cov-2
WO2026092136A1 (en) Combo vaccines for respiratory diseases
WO2016115664A1 (en) 3d protein-specific monoclonal immunoglobulin a antibodies
Voloshchuk et al. CLINICAL-LABORATORY CHARACTERISTICS OF INFLUENZA INFECTION IN HOSPITALIZED ADULT PATIENTS IN THE EPIDEMIC SEASON 2017–2018
Rigter et al. A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant
BR122024015865A2 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção
BR112016007868B1 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250107

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250107

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250217

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250305

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250528

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251215

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251215